+ Follow DAVID ELSAPUTRA Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 325104
[Title] => BFAD okays entecavir for treatment of chronic hepa B
[Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.
The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver. The drug will be available in the Philippines in the first quarter of 2006.
[DatePublished] => 2006-03-09 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 318537
[Title] => BFAD approves entecavir
[Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.
The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver.
The drug will be available in the Philippines in the first quarter.
[DatePublished] => 2006-01-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
DAVID ELSAPUTRA
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 325104
[Title] => BFAD okays entecavir for treatment of chronic hepa B
[Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.
The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver. The drug will be available in the Philippines in the first quarter of 2006.
[DatePublished] => 2006-03-09 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 318537
[Title] => BFAD approves entecavir
[Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.
The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver.
The drug will be available in the Philippines in the first quarter.
[DatePublished] => 2006-01-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
January 26, 2006 - 12:00am
